Post‐colonoscopy upper gastrointestinal malignancies in positive immunochemical fecal occult blood test patients: An Australian data linkage study
Journal of Gastroenterology and Hepatology · 2024-12 · 39 (12) · 2811-2816
DOI: 10.1111/jgh.16799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 06.11.2024. Verfasst von Sahar Pakneshan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Occult Blood, Colonoscopy, Stomach Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background and Aim In immunochemical fecal occult blood test (iFOBT) positive subjects, colonoscopy screening can detect colorectal cancers and advanced adenomas, yet most iFOBT‐positive subjects find no relevant lower gastrointestinal lesions. Limited data are available on upper gastrointestinal (UGI) cancer risk in iFOBT‐positive patients. This study investigated the incidence of UGI malignancies diagnosed within 3 years post‐colonoscopy after a positive iFOBT.
Methods
Retrospective analysis of iFOBT‐positive patients aged 50–75 years who underwent a colonoscopy at a single institution. All patients with a diagnosis of UGI cancer within 3 years post‐colonoscopy were identified by linking with the Queensland Cancer Register. This was used to compare to the geographical population aged 50–74 years based on the Australian Bureau of Statistics and Queensland Cancer Council data.
Results
From 1748 eligible participants, 0.23% (95% confidence interval [CI] 0.06–0.58) were diagnosed with UGI cancer within 3 years post‐colonoscopy. This indicates an esophageal cancers rate of 114.42 per 100 000 (95% CI 100.56–298.28) and gastric cancer rate of 57.21 per 100 000 (95% CI 55.76–261.12). Of the patients with a UGI cancer, 75% would have had an unexplained iFOBT. Annual incidence for the same geographic region, ages, and period for the combined esophageal and gastric cancer was 36.08 per 100 000 (95% CI 32.87–39.52).
Conclusions
Among individuals with a positive iFOBT in a bowel cancer screening program, the rates of gastric and esophageal cancers were 2.7 and 7.5 times higher than the general population. Adding gastroscopy to a colonoscopy for iFOBT‐positive patients in cancer surveillance programs may be justifiable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
- Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
- Translational Research Institute, Brisbane, Queensland, Australia.
- Department of Psychology, Macquarie University, Sydney, New South Wales, Australia.
- Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia.
ORCID-Profile: Naomi Moy, Nicholas J Talley, Gerald Holtmann
Zitieren
APA
Pakneshan, S., Moy, N., Shah, A., Koloski, N., Jones, M. P., Talley, N. J., & Holtmann, G. (2024). Post‐colonoscopy upper gastrointestinal malignancies in positive immunochemical fecal occult blood test patients: An Australian data linkage study. Journal of Gastroenterology and Hepatology, 39(12), 2811-2816. https://doi.org/10.1111/jgh.16799
Vancouver
Pakneshan S, Moy N, Shah A, Koloski N, Jones MP, Talley NJ, et al. Post‐colonoscopy upper gastrointestinal malignancies in positive immunochemical fecal occult blood test patients: An Australian data linkage study. Journal of Gastroenterology and Hepatology. 2024;39(12):2811-2816. doi:10.1111/jgh.16799
BibTeX
@article{Pakneshan2024,
author = {Pakneshan, Sahar and Moy, Naomi and Shah, Ayesha and Koloski, Natasha and Jones, Mike P and Talley, Nicholas J and Holtmann, Gerald},
title = {Post‐colonoscopy upper gastrointestinal malignancies in positive immunochemical fecal occult blood test patients: An Australian data linkage study},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
volume = {39},
number = {12},
pages = {2811--2816},
doi = {10.1111/jgh.16799}
}
EUVIMED